Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
Authors
Tony R. Reid
EpicentRx, Inc., La Jolla, CA;
Tony R. Reid , Nacer Abrouk , Bryan Oronsky , Scott Caroen , George A. Fisher Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02096354
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 97)
DOI
10.1200/JCO.2023.41.4_suppl.97
Abstract #
97
Poster Bd #
E14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer.
First Author: Tony R. Reid
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2024 ASCO Annual Meeting
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.
First Author: Kanwal Pratap Singh Raghav